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Rectal or intramuscular diclofenac reduces the incidence of pancreatitis after
endoscopic retrograde cholangiopancreatography
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Background/aim: Acute pancreatitis is the most common adverse event of endoscopic retrograde cholangiopancreatography (ERCP).
We aimed to evaluate the efficacy of intramuscular diclofenac sodium for prophylaxis of post-ERCP pancreatitis (PEP) in comparison
to the rectal form.
Materials and methods: One hundred and fifty consecutive patients who underwent ERCP were enrolled in this single-center,
prospective, randomized controlled study. Patients were randomized into three groups. The first group received 75 mg of diclofenac
sodium via intramuscular route and the second group received 100 mg of diclofenac sodium rectally 30–90 min before the procedure.
The third group served as the control group. Patients were evaluated for post-ERCP pancreatitis with serum amylase levels and
abdominal pain 24 h after the procedure.
Results: The overall incidence of PEP was 6% (n = 9) and 2% (n = 1) in the intramuscular (IM) and rectal groups, respectively, and 14%
in the control group (P = 0.014). Nineteen (12.7%) patients developed post-ERCP abdominal pain (8% in IM, 10% in rectal, and 20%
in control group; P = 0.154). Twenty-five (16.6%) patients developed post-ERCP hyperamylasemia (10% in IM, 12% in rectal, and 24%
in control group; P = 0.03).
Conclusion: Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP
pancreatitis.
Key words: Diclofenac, ERCP, post-ERCP pancreatitis

1. Introduction
Endoscopic retrograde cholangiopancreatography (ERCP)
is the procedure with the highest rate of adverse events
among all gastrointestinal endoscopic procedures. PostERCP pancreatitis (PEP) is the most common adverse
event of ERCP (1). PEP occurs in about 1%–10% of
patients undergoing ERCP but most of the cases are mild
or moderate (2). Several drugs have been studied for the
pharmacologic prophylaxis of PEP, including relaxation of
the sphincter of Oddi, reduction of pancreatic secretions,
prevention of infection, and restriction of inflammatory
response, which yielded controversial results (1).
In recent years, nonsteroidal antiinflammatory
drugs (NSAIDs), particularly diclofenac sodium, have
been successfully used for PEP prophylaxis. A single
administration of diclofenac, by rectal or intramuscular
(IM) route, has been studied either before or after the
ERCP procedure for prevention of PEP (3–5). Diclofenac
* Correspondence: mdramazan@gmail.com

is an inexpensive, commonly available, easily administered
drug that is safe for single use.
In this study, we aimed to compare the efficacy of
IM diclofenac sodium with that of the rectal form for
prevention of PEP.
2. Materials and methods
One hundred and fifty patients who underwent ERCP
in the Gastroenterology Department between January
2011 and September 2012 were consecutively enrolled
in this single-center, prospective, randomized controlled
study. Patients with acute pancreatitis using NSAIDs
or acetylsalicylic acid during the previous week with
creatinine levels above 2 mg/dL, those with a known
allergy to diclofenac, pregnant and breastfeeding women,
patients who were recently diagnosed with peptic ulcer,
and those with a history of endoscopic sphincterotomy
were excluded. Patients were consecutively randomized
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into three groups. The first group received 75 mg of
diclofenac sodium intramuscularly and the second group
received 100 mg of diclofenac sodium via rectal route
30–90 min before the procedure. The third group did not
receive any prophylaxis and served as the control group.
The study was approved by the local ethics committee and
all patients gave written informed consent.
All ERCP procedures were performed by same
endoscopist. The endoscopist was blinded to treatment
allocation and recorded the following information during
the procedure: the difficulty of cannulation, diagnosis
made during ERCP, presence of periampullary diverticula,
total duration of the procedure, insertion of guide wire
into the pancreatic duct, opacification of the pancreas,
and adverse events, if any, during the procedure and
interventions such as sphincterotomy, balloon dilation,
and stenting. Difficult cannulation was defined as needing
more than 5 attempts and/or 10 min of manipulation time.
We performed suprapapillary fistulotomy with needle
knife for patients with difficult cannulation and standard
sphincterotomy for all other patients.
Serum amylase levels were measured at 4 and 24 h of
the procedure, and oral intake of water was permitted for
patients with serum amylase levels less than 3 times the
upper limit of normal (ULN) (375 U/L) at 4 h.
Patients were evaluated for PEP according to the
criteria described by Cotton et al., which included an
increase in serum amylase levels 3 times greater than
the ULN and new-onset or worsened abdominal pain
lasting more than 24 h after the procedure (6). Post-ERCP
hyperamylasemia was considered when serum amylase
levels were 3 times greater than the ULN within 24 h
after ERCP. Severity of pancreatitis was defined on the
basis of the duration of hospitalization after procedure;
2–3 days of hospital stay was required for mild PEP, 4–10
days for moderate PEP, and >10 days for severe PEP and/
or necrotizing pancreatitis and any surgical interventions
related to PEP (6).

2.1. Statistical analysis
Statistical analyses were performed using SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL, USA). The Student
t-test and the chi-square test were used for groups showing
normal distribution and the Mann–Whitney U test was
used for groups with nonnormal distribution. The oneway ANOVA test was used to examine the differences
between multiple groups. The Wilcoxon test was used
to determine differences between intragroup repeated
measures. Continuous variables were expressed as means
with standard deviations. Statistical significance was set at
P < 0.05.
3. Results
A total 150 patients (100 females and 50 males) with a
mean age of 60.2 ± 17.6 years were enrolled in the study.
The three groups were similar with respect to age, sex,
indication, procedures performed during ERCP, diagnosis,
and other factors associated with increased risk for PEP, as
shown in Tables 1–3.
The mean serum amylase levels were statistically
significantly higher (P = 0.05) in the control group
compared to both diclofenac groups at 4 h [183 ± 38 (SE)
U/L in IM group, 214 ± 61 U/L in rectal group, and 487 ±
148 U/L in control group] and at 24 h after ERCP (140 ±
20 U/L in IM group, 211 ± 77 U/L in rectal group, and 463
± 100 U/L in control group; P < 0.05).
Nineteen (12.7%) patients reported new-onset
abdominal pain at 24 h after ERCP (n = 4, IM group; n =
5, rectal group; n = 10, control group). The incidence of
abdominal pain was higher in the control group compared
to the IM and rectal groups, but the difference was not
statistically significant (P = 0.15). Twenty-five (16.6%)
patients developed post-ERCP hyperamylasemia (n =
5, IM group; n = 6, rectal group; n = 14, control group),
which occurred significantly more frequently in the
control group (P < 0.05).
A total of 9 (6%) patients had PEP (n = 1, IM group;
n = 1 rectal group; n = 7, control group), which was

Table 1. Characteristics and demographic data of patients.
Intramuscular
(n = 50)

Rectal
(n = 50)

Control
(n = 50)

P-value

Sex (male/female)

17/33

13/37

20/30

0.334

Age (years)

61.1 ± 16.8

59 ± 18.6

60.5 ± 17.6

0.830

Body mass index (kg/m2)

26.2 ± 3.0

27.6 ± 3.3

26.5 ± 2.9

0.058

Total bilirubin (mg/dL)

4.1 ± 0.6

4.2 ± 0.8

4.4 ± 0.9

0.954

Data are presented as number/number or mean ± standard deviation, as appropriate.
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Table 2. Indications for endoscopic retrograde cholangiopancreatography.
Intramuscular
(n = 50)

Rectal
(n = 50)

Control
(n = 50)

Choledocholithiasis

40

47

36

Periampullary tumor

7

1

10

Benign biliary stenosis

1

1

-

Other

2

1

4

Data are presented as numbers.
Table 3. Endoscopic findings and therapeutic procedures during endoscopic retrograde cholangiopancreatography.
Intramuscular

Rectal

Control

P-value

Total duration (min)

24 ± 12

20 ± 11

25 ± 11

0.073

Difficult cannulation

8

11

15

0.309

Insertion of guide wire into the pancreatic duct

15

16

21

0.402

Pancreatic opacification

7

4

-

0.027

Suprapapillary fistulotomy with needle knife

8

9

11

0.619

Diverticula (peridiverticular/intradiverticular papilla)

3/4

9/4

5/4

0.440

Balloon catheter for stone extraction

33

36

39

0.398

Basket catheter for stone extraction

5

6

8

0.662

Lithotripsy

0

4

4

0.118

Biliary stenting

11

6

10

0.413

Data are presented as number, number/number, or mean ± standard deviation, as appropriate.

significantly more common in the control group (P <
0.05). Four of them had mild PEP (n = 1, IM group; n =
3, control group) and 5 had moderate PEP (n = 1, rectal
group; n = 4, control group).
The median of duration of hospital stay was significantly
longer in the control group compared to the diclofenac
groups (1 day in IM group, 1 day in rectal group, and 2
days in control group, P < 0.001; Table 4).
Four of the patients (2 in IM and 2 in rectal group)
had self-limiting bleeding, which stopped spontaneously
during the procedure and did not require any intervention.
We did not use pancreatic stents in any of the patients, and
no adverse effects were observed after administration of a
single dose of NSAIDs in the diclofenac groups.
4. Discussion
In the present study we found that: 1) diclofenac, whether
administered rectally or intramuscularly, reduced the

incidence of PEP; 2) abdominal pain was less common in
the diclofenac groups compared to the control group; 3)
post-ERCP hyperamylasemia occurred at a significantly
lower rate in the diclofenac groups in comparison to the
control group; and 4) duration of hospitalization was
significantly shorter in both diclofenac groups compared
to the control group.
Three metaanalyses, which gathered data from 4
randomized, controlled trials on NSAIDs (two studies each
with diclofenac and indomethacin), were published for
PEP prophylaxis (7–9). Murray et al. (4) and Khoshbaten
et al. (3) reported that 100 mg of diclofenac administered
rectally significantly reduced the incidence of PEP. In a
recent study by Otsuka et al. in Japanese patients, 50 mg of
diclofenac given by the rectal route was found to be effective
for prevention of PEP, post-ERCP hyperamylasemia, and
abdominal pain (2). Senol et al. administered diclofenac
by intramuscular route for preventing PEP for the first
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Table 4. Outcome measures of the study groups.
Intramuscular

Rectal

Control

P-value

1

1

7

0.014

Mild

-

1

3

Moderate

1

-

4

Severe

-

-

-

Abdominal pain

4

5

10

0.154

Amylase, at 4 h (U/L)

183 ± 38

214 ± 61

487 ± 148

0.05

Amylase, at 24 h (U/L)

140 ± 20

211 ± 77

463 ± 100

0.006

Post-ERCP hyperamylasemia

5

6

14

0.03

Duration of hospitalization after ERCP (days) (min/median/max)

1/1/4

1/1/3

1/2/8

<0.001

Post-ERCP pancreatitis

ERCP: Endoscopic retrograde cholangiopancreatography.
Data are presented as number, mean ± standard deviation, or minimum/median/maximum, as appropriate.

time and found that diclofenac nonsignificantly lowered
PEP incidence (5). In the current study, the incidence of
PEP was equal in the rectal and intramuscular diclofenac
groups and significantly lower compared to the control
group.
Inflammatory response of the patient due to irritation
of the pancreatic duct is an important cause of PEP (10,11).
NSAIDs have potent effects on inhibiting phospholipase
A2, which plays a crucial role in the initial steps of the
inflammatory cascade (12). The peak serum concentration
of diclofenac occurs at 30–90 min after administration
and the elimination half-life is 2 h (13). Any concern that
diclofenac may mask abdominal pain during evaluation of
PEP is unlikely because the analgesic effect of diclofenac
is not maintained for 24 h. Diclofenac, which is an
NSAID, is an inexpensive, widely available, and easily
administered drug and it has a safe adverse effect profile.
In the present study, there were no severe adverse effects
associated with diclofenac. Rectal administration of
diclofenac or indomethacin before or after ERCP has been
recommended for prophylaxis of PEP by the most recent
guideline of the European Society of Gastrointestinal
Endoscopy (ESGE) (1).
In addition to NSAID prophylaxis, in the case of high
risk for PEP, prophylactic pancreatic stent placement
is recommended by ESGE guidelines (14). However,
a metaanalysis showed that prophylactic pancreatic
stenting alone was less effective than NSAIDs alone, and
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the combination of NSAIDs with prophylactic pancreatic
stenting did not further decrease the risk of PEP (15). In
our study, we did not place any pancreatic stents, because
we aimed to evaluate the role of diclofenac for PEP
prophylaxis. Additional pancreatic canal implementation
could also increase the risk of PEP. There are several
pharmacological agents studied for PEP prophylaxis,
but findings are controversial. Only glyceryl trinitrate
(sublingually) or somatostatin (bolus injection) have
been found to be possibly effective agents and might be
considered as an option in high-risk cases if NSAIDs are
contraindicated and if prophylactic pancreatic stenting is
not possible (14).
Although we aimed to compare the effectiveness of IM
and rectal forms of diclofenac for prophylaxis of PEP, the
incidence of PEP was the same in both groups; hence, no
statistical comparison was made between these groups.
Female sex, age less than 60 years, normal serum
bilirubin levels, difficult cannulation, and pancreatic
opacification are well-known risk factors for PEP. In the
current study, these factors were more common in patients
developing PEP, but the difference was not statistically
significant.
In conclusion, this study showed that both rectal
and intramuscular forms of diclofenac are successful in
preventing PEP. We think that diclofenac administered
rectally or intramuscularly is a safe, inexpensive, and
simple method for PEP prophylaxis.
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